Abstract
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10–8) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated with colchicine (placebo), there was a significant association at 9q33.1 (rs62575331; P = 2.95 × 10–8) in interaction with colchicine (P = 1.19 × 10–5) without impact on risk of hospitalisations, highlighting a possibly shared mechanistic pathway. By day 15 of the study, 46%, 62% and 64% of those with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. The findings need to be replicated and could contribute to the biological understanding of COVID-19 symptom remission.
Highlights
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial
In a prespecified analysis of 4159 participants who received a diagnosis of COVID-19 confirmed by a polymerase chain reaction (PCR) test, the primary endpoint occurred in 4.6% and 6.0% of patients in the colchicine and placebo groups respectively[9]
We conducted a genetic study of time to remission of COVID-19 symptoms assessed during the 30-day follow up period of the COLCORONA clinical trial, with the aim to gain a better understanding of the underlying factors responsible for the duration of symptoms in the acute phase of disease in a recently diagnosed outpatient population
Summary
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. The COLCORONA randomised clinical trial compared the benefit of low-dose colchicine to placebo in 4488 outpatient individuals diagnosed with a COVID-19 infection who were 40 years or older and with at least one high-risk criterion for severe d isease[9]. We conducted a genetic study of time to remission of COVID-19 symptoms assessed during the 30-day follow up period of the COLCORONA clinical trial, with the aim to gain a better understanding of the underlying factors responsible for the duration of symptoms in the acute phase of disease in a recently diagnosed outpatient population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
